PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34791636-14	2021	iBET-151 plus paclitaxel significantly promoted cell cycle arrest and apoptosis and suppressed c-Myc, Bcl-2 and Bcl-xL expression.	GSK1210151A	0-8	B cell leukemia/lymphoma 2	Mus musculus	102-107
34791636-14	2021	iBET-151 plus paclitaxel significantly promoted cell cycle arrest and apoptosis and suppressed c-Myc, Bcl-2 and Bcl-xL expression.	GSK1210151A	0-8	BCL2-like 1	Mus musculus	112-118
34791636-4	2021	METHODS: The effect of BET inhibition was evaluated using iBET-151, a small-molecule inhibitor of BET proteins, in a large panel (n = 49) of GC cell lines and xenograft mouse models.	GSK1210151A	58-66	delta/notch-like EGF repeat containing	Mus musculus	98-101
34791636-12	2021	In GC xenograft model mice, iBET-151 significantly decreased tumor volumes and Ki-67 and BRD4 expression.	GSK1210151A	28-36	antigen identified by monoclonal antibody Ki 67	Mus musculus	79-84
34791636-16	2021	CONCLUSIONS: Collectively, our data suggest that iBET-151 is a potential therapeutic agent for GC, especially in combination with paclitaxel, and that WNT5B and IRS2 may predict iBET-151 sensitivity.	GSK1210151A	49-57	wingless-type MMTV integration site family, member 5B	Mus musculus	151-156
34791636-12	2021	In GC xenograft model mice, iBET-151 significantly decreased tumor volumes and Ki-67 and BRD4 expression.	GSK1210151A	28-36	bromodomain containing 4	Mus musculus	89-93
34791636-16	2021	CONCLUSIONS: Collectively, our data suggest that iBET-151 is a potential therapeutic agent for GC, especially in combination with paclitaxel, and that WNT5B and IRS2 may predict iBET-151 sensitivity.	GSK1210151A	49-57	insulin receptor substrate 2	Mus musculus	161-165
30971469-6	2019	Little is known about BETi efficacy in activating HIV-1 reservoir cells under cART in vivo Here we report that a BETi (I-BET151) efficiently activated HIV-1 reservoirs under effective cART in humanized mice in vivo Interestingly, I-BET151 during suppressive cART in vivo activated HIV-1 gene expression only in monocytic cells and not in CD4+ T cells.	GSK1210151A	119-127	CD4 molecule	Homo sapiens	338-341
33664670-3	2021	Expression levels of bromodomain-containing protein 2 and 4, but not 3 were increased in the kidney of rats with HN; administration of I-BET151 effectively prevented renal dysfunction, decreased urine microalbumin, and attenuated renal fibrosis as indicated by reduced activation of renal interstitial fibroblasts and expression of fibronectin and collagen I in HN rats.	GSK1210151A	135-143	bromodomain-containing protein 2	Rattus norvegicus	21-59
33664670-3	2021	Expression levels of bromodomain-containing protein 2 and 4, but not 3 were increased in the kidney of rats with HN; administration of I-BET151 effectively prevented renal dysfunction, decreased urine microalbumin, and attenuated renal fibrosis as indicated by reduced activation of renal interstitial fibroblasts and expression of fibronectin and collagen I in HN rats.	GSK1210151A	135-143	fibronectin 1	Rattus norvegicus	332-343
31882553-3	2020	RESULTS: Treatment with BRD4 inhibitor I-BET151 exerted a dose-dependent inhibitory effect on cell proliferation in MCL cell lines.	GSK1210151A	39-47	bromodomain containing 4	Homo sapiens	24-28
34540687-1	2021	I-BET151 is an inhibitor of bromodomain and extra-terminal domain (BET) proteins that selectively inhibits BET family members (BRD2, BRD3, BRD4, and BRDT).	GSK1210151A	0-8	bromodomain containing 2	Homo sapiens	127-131
34540687-1	2021	I-BET151 is an inhibitor of bromodomain and extra-terminal domain (BET) proteins that selectively inhibits BET family members (BRD2, BRD3, BRD4, and BRDT).	GSK1210151A	0-8	bromodomain containing 3	Homo sapiens	133-137
34540687-1	2021	I-BET151 is an inhibitor of bromodomain and extra-terminal domain (BET) proteins that selectively inhibits BET family members (BRD2, BRD3, BRD4, and BRDT).	GSK1210151A	0-8	bromodomain containing 4	Homo sapiens	139-143
34540687-1	2021	I-BET151 is an inhibitor of bromodomain and extra-terminal domain (BET) proteins that selectively inhibits BET family members (BRD2, BRD3, BRD4, and BRDT).	GSK1210151A	0-8	bromodomain testis associated	Homo sapiens	149-153
34336707-5	2021	We found that super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.	GSK1210151A	51-59	interleukin 20 receptor subunit alpha	Homo sapiens	129-136
35239184-9	2022	H3K27ac enrichment was similar at the DGKA enhancer region after I-BET151 treatment and irradiation, but was reduced at the COL1A1 transcription start site and the ACTA2 enhancer site.	GSK1210151A	65-73	diacylglycerol kinase alpha	Homo sapiens	38-42
35196077-3	2022	Here, through chemical screening, we demonstrate that the bromodomain and extraterminal domain (BET) inhibitor I-BET151 can robustly promote the expansion of PDX1+NKX6.1+ pancreatic progenitors (PPs).	GSK1210151A	111-119	pancreatic and duodenal homeobox 1	Homo sapiens	158-162
35196077-3	2022	Here, through chemical screening, we demonstrate that the bromodomain and extraterminal domain (BET) inhibitor I-BET151 can robustly promote the expansion of PDX1+NKX6.1+ pancreatic progenitors (PPs).	GSK1210151A	111-119	NK6 homeobox 1	Homo sapiens	163-169
33664670-8	2021	Collectively, our results indicate that I-BET151 alleviates HN by inhibiting epithelial to mesenchymal transition and inflammation in association with blockade of TGF-beta, ERK1/2 and NF-kappaB signaling.	GSK1210151A	40-48	transforming growth factor alpha	Rattus norvegicus	163-171
33664670-8	2021	Collectively, our results indicate that I-BET151 alleviates HN by inhibiting epithelial to mesenchymal transition and inflammation in association with blockade of TGF-beta, ERK1/2 and NF-kappaB signaling.	GSK1210151A	40-48	mitogen activated protein kinase 3	Rattus norvegicus	173-179
33193257-7	2020	Treatment with I-BET151, an inhibitor of Brd/BET, displaced kLANA and Brd2/4 from TSS in the viral and host chromatin, but did not affect the direct binding of kLANA to kLANA-binding sites (LBS) in the KSHV latent origin of replication.	GSK1210151A	15-23	bromodomain containing 2	Homo sapiens	70-76
32913560-0	2020	The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling.	GSK1210151A	26-34	GLI family zinc finger 1	Homo sapiens	121-124
32913560-5	2020	Furthermore, we examine the role of GLI1 in tumorigenicity of EAC and how a selective bromodomain inhibitor IBET-151 downregulates transcriptional activity of the GLI1 transcription factor in EAC.	GSK1210151A	108-116	GLI family zinc finger 1	Homo sapiens	163-167
32913560-7	2020	Importantly, IBET-151 abrogates the growth of vismodegib-resistant EAC cells and downregulates HH/GLI by reducing the occupancy of BRD4 at the GLI1 locus.	GSK1210151A	13-21	GLI family zinc finger 1	Homo sapiens	98-101
32913560-7	2020	Importantly, IBET-151 abrogates the growth of vismodegib-resistant EAC cells and downregulates HH/GLI by reducing the occupancy of BRD4 at the GLI1 locus.	GSK1210151A	13-21	bromodomain containing 4	Homo sapiens	131-135
32913560-7	2020	Importantly, IBET-151 abrogates the growth of vismodegib-resistant EAC cells and downregulates HH/GLI by reducing the occupancy of BRD4 at the GLI1 locus.	GSK1210151A	13-21	GLI family zinc finger 1	Homo sapiens	143-147
32913560-8	2020	IBET-151 also attenuates tumor growth of EAC-PDXs and does so in an on-target manner as it reduces the expression of GLI1.	GSK1210151A	0-8	GLI family zinc finger 1	Homo sapiens	117-121
32913560-10	2020	Therefore, we propose that selective bromodomain inhibitors, such as IBET-151, could be used as novel therapeutic agents for EAC patients harboring GLI-dependent tumors.	GSK1210151A	69-77	GLI family zinc finger 1	Homo sapiens	148-151
30971469-11	2019	Furthermore, I-BET151 significantly increased HIV-1 transcription in monocytic cells, but not in HIV-1-infected CD4 T cells, via CDK2-dependent mechanisms.	GSK1210151A	13-21	cyclin dependent kinase 2	Homo sapiens	129-133
30786900-3	2019	And a BET protein inhibitor, I-BET151, has been shown to inhibit the induction of matrix-degrading enzymes by proinflammatory cytokines in chondrocytes.	GSK1210151A	29-37	delta/notch like EGF repeat containing	Homo sapiens	6-9
31024538-0	2019	BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation.	GSK1210151A	26-33	delta/notch like EGF repeat containing	Homo sapiens	0-3
31024538-3	2019	We isolated human ILC2 and examined the capacity of the BET protein inhibitor, iBET151, to modulate human ILC2 activation following IL-33 stimulation.	GSK1210151A	79-86	delta/notch like EGF repeat containing	Homo sapiens	56-59
31024538-3	2019	We isolated human ILC2 and examined the capacity of the BET protein inhibitor, iBET151, to modulate human ILC2 activation following IL-33 stimulation.	GSK1210151A	79-86	interleukin 33	Homo sapiens	132-137
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	interleukin 1 beta	Homo sapiens	55-64
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	tumor necrosis factor	Homo sapiens	68-77
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	matrix metallopeptidase 1	Homo sapiens	100-104
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	matrix metallopeptidase 3	Homo sapiens	106-110
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	matrix metallopeptidase 13	Homo sapiens	112-117
30786900-8	2019	RESULTS: We confirmed that I-BET151 could suppress the IL-1beta- or TNF-alpha-induced expression of MMP1, MMP3, MMP13, and ADAMTS4 in SW1353 cells.	GSK1210151A	27-35	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	123-130
30249811-6	2018	RMD+IBET151 treatment significantly increased the frequency of vaccine-elicited IFN-gamma+ splenic CD8+ T cells and conferred superior therapeutic and prophylactic protection against B16-OVA melanoma.	GSK1210151A	4-11	interferon gamma	Mus musculus	80-89
29067128-0	2017	I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.	GSK1210151A	0-8	TNF superfamily member 11	Homo sapiens	32-37
30300821-0	2018	NF-kappaB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.	GSK1210151A	110-118	bromodomain containing 2	Homo sapiens	48-52
30300821-0	2018	NF-kappaB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.	GSK1210151A	110-118	bromodomain containing 4	Homo sapiens	57-61
30300821-3	2018	In the present study, we evaluated the mechanism of resistance to the BET inhibitor I-BET151 and its signaling pathway to overcome resistance in U937 cells.	GSK1210151A	84-92	delta/notch like EGF repeat containing	Homo sapiens	70-73
30111428-2	2018	METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages.	GSK1210151A	51-59	delta/notch like EGF repeat containing	Homo sapiens	23-26
30111428-2	2018	METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages.	GSK1210151A	249-257	delta/notch like EGF repeat containing	Homo sapiens	23-26
30111428-2	2018	METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages.	GSK1210151A	249-257	delta/notch like EGF repeat containing	Homo sapiens	23-26
30153557-4	2018	We report our studies on the concomitant use of the BRD4 inhibitor I-BET151 and AURKA inhibitor alisertib.	GSK1210151A	67-75	bromodomain containing 4	Homo sapiens	52-56
29748211-6	2018	We reported that I-BET151 is able to arrest the growth of MLL-AF4+ leukemic cells in vitro, by blocking cell division and rapidly inducing apoptosis.	GSK1210151A	17-25	lysine methyltransferase 2A	Homo sapiens	58-61
29748211-6	2018	We reported that I-BET151 is able to arrest the growth of MLL-AF4+ leukemic cells in vitro, by blocking cell division and rapidly inducing apoptosis.	GSK1210151A	17-25	AF4/FMR2 family member 1	Homo sapiens	62-65
29784003-2	2018	And a BET protein inhibitor, I-BET151, has been shown to exert an anti-inflammatory effect by repressing the BET protein-mediated expression of inflammatory genes.	GSK1210151A	29-37	delta/notch-like EGF repeat containing	Mus musculus	6-9
29784003-8	2018	I-BET151 could robustly suppress the IL-1beta- and TNF-alpha-induced expression and activity of several matrix-degrading enzymes in human chondrocytes.	GSK1210151A	0-8	interleukin 1 beta	Homo sapiens	37-45
29784003-8	2018	I-BET151 could robustly suppress the IL-1beta- and TNF-alpha-induced expression and activity of several matrix-degrading enzymes in human chondrocytes.	GSK1210151A	0-8	tumor necrosis factor	Homo sapiens	51-60
29240787-3	2017	We evaluated the in vitro and in vivo efficacy of the BRD3/4 inhibitor I-BET151 in various human MLL-AF9 (primary) models and patient samples and analyzed the transcriptome changes following treatment.	GSK1210151A	71-79	bromodomain containing 3	Homo sapiens	54-58
29240787-3	2017	We evaluated the in vitro and in vivo efficacy of the BRD3/4 inhibitor I-BET151 in various human MLL-AF9 (primary) models and patient samples and analyzed the transcriptome changes following treatment.	GSK1210151A	71-79	lysine methyltransferase 2A	Homo sapiens	97-104
28983590-0	2017	I-BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.	GSK1210151A	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	45-50
28983590-7	2017	TRACP staining results demonstrated that I-BET151 inhibited osteoclastogenesis induced by RANKL and the inhibition was dose dependent.	GSK1210151A	41-49	acid phosphatase 5, tartrate resistant	Mus musculus	0-5
28983590-7	2017	TRACP staining results demonstrated that I-BET151 inhibited osteoclastogenesis induced by RANKL and the inhibition was dose dependent.	GSK1210151A	41-49	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	90-95
28983590-9	2017	The inhibitory effect on TRAF6 was significant when concentrations of 100 and 200 nM I-BET151 were used, and NFATcl was significantly inhibited when a concentration of 200 nM was used compared with the RANKL group, in a dose-dependent manner.	GSK1210151A	85-93	TNF receptor-associated factor 6	Mus musculus	25-30
28983590-10	2017	Nuclear translocation of p65 was significantly inhibited by I-BET151 at all concentrations.	GSK1210151A	60-68	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	25-28
28983590-11	2017	The degradation of IkappaB-alpha, and phosphorylation of JNK and p38 were also significantly inhibited by I-BET151, with the exception of the expression of IkappaB-alpha following treatment with 50 nM I-BET151.	GSK1210151A	106-114	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	19-32
28983590-11	2017	The degradation of IkappaB-alpha, and phosphorylation of JNK and p38 were also significantly inhibited by I-BET151, with the exception of the expression of IkappaB-alpha following treatment with 50 nM I-BET151.	GSK1210151A	106-114	mitogen-activated protein kinase 8	Mus musculus	57-60
28983590-11	2017	The degradation of IkappaB-alpha, and phosphorylation of JNK and p38 were also significantly inhibited by I-BET151, with the exception of the expression of IkappaB-alpha following treatment with 50 nM I-BET151.	GSK1210151A	106-114	mitogen-activated protein kinase 14	Mus musculus	65-68
29067128-0	2017	I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.	GSK1210151A	0-8	matrix metallopeptidase 3	Homo sapiens	44-48
29067128-0	2017	I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.	GSK1210151A	0-8	matrix metallopeptidase 9	Homo sapiens	53-57
29067128-6	2017	A HLA-B27/beta2m transgenic AS Lewis rat model was established and treated with 30 mg/kg I-BET151 for 5 weeks.	GSK1210151A	89-97	major histocompatibility complex, class I, B	Homo sapiens	2-9
29067128-0	2017	I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.	GSK1210151A	0-8	TNF receptor superfamily member 11b	Homo sapiens	39-42
21964340-5	2011	We show that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis.	GSK1210151A	65-76	delta/notch like EGF repeat containing	Homo sapiens	53-56
28653617-3	2017	We found treatment of MLL-fusion leukaemia cells (MV4;11 cell line) with the BET bromodomain inhibitor I-BET151 resulted in selective growth inhibition, whereas treatment of leukaemia cells harboring a different oncogenic driver (K-562 cell line) did not result in selective growth inhibition; this is similar to the findings reported in the original study (Figure 2A and Supplementary Figure 11A,B; Dawson et al., 2011).	GSK1210151A	103-111	delta/notch like EGF repeat containing	Homo sapiens	77-80
28653617-4	2017	Further, I-BET151 resulted in a statistically significant decrease in BCL2 expression in MV4;11 cells, but not in K-562 cells; again this is similar to the findings reported in the original study (Figure 3D; Dawson et al., 2011).	GSK1210151A	9-17	BCL2 apoptosis regulator	Homo sapiens	70-74
28322577-5	2017	In vivo treatment of ozone-exposed mice with the BET inhibitor IBET151 similarly inhibited ozone-induced immunoglobulin production.	GSK1210151A	63-70	delta/notch-like EGF repeat containing	Mus musculus	49-52
24924589-0	2014	Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.	GSK1210151A	96-104	nuclear factor kappa B subunit 1	Homo sapiens	11-16
24924589-3	2014	In this study, we have examined the ability of the bromodomain and extra-terminal (BET) protein inhibitor I-BET151 to inhibit NF-kB in melanoma cells.	GSK1210151A	106-114	delta/notch like EGF repeat containing	Homo sapiens	83-86
24924589-3	2014	In this study, we have examined the ability of the bromodomain and extra-terminal (BET) protein inhibitor I-BET151 to inhibit NF-kB in melanoma cells.	GSK1210151A	106-114	nuclear factor kappa B subunit 1	Homo sapiens	126-131
24924589-4	2014	We show that I-BET151 is a potent, selective inhibitor of a number of NF-kB target genes involved in induction of inflammation and cell cycle regulation and downregulates production of cytokines such as IL-6 and IL-8.	GSK1210151A	13-21	nuclear factor kappa B subunit 1	Homo sapiens	70-75
24924589-4	2014	We show that I-BET151 is a potent, selective inhibitor of a number of NF-kB target genes involved in induction of inflammation and cell cycle regulation and downregulates production of cytokines such as IL-6 and IL-8.	GSK1210151A	13-21	interleukin 6	Homo sapiens	203-207
24924589-4	2014	We show that I-BET151 is a potent, selective inhibitor of a number of NF-kB target genes involved in induction of inflammation and cell cycle regulation and downregulates production of cytokines such as IL-6 and IL-8.	GSK1210151A	13-21	C-X-C motif chemokine ligand 8	Homo sapiens	212-216
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	interleukin 6	Mus musculus	29-33
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	delta/notch-like EGF repeat containing	Mus musculus	77-80
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	tumor necrosis factor	Mus musculus	260-268
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	interleukin 1 beta	Mus musculus	270-278
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	interleukin 10	Mus musculus	283-288
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	314-321	interleukin 6	Mus musculus	29-33
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	314-321	delta/notch-like EGF repeat containing	Mus musculus	77-80
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	314-321	delta/notch-like EGF repeat containing	Mus musculus	119-122
24859008-4	2014	I-BET151 prevented the binding of CBP to the promoter of IL-6, but I-BET151 did not affect acetylation, phosphorylation, nuclear translocation, or DNA binding of p65-NF-kappaB.	GSK1210151A	0-8	CREB binding protein	Mus musculus	34-37
24859008-4	2014	I-BET151 prevented the binding of CBP to the promoter of IL-6, but I-BET151 did not affect acetylation, phosphorylation, nuclear translocation, or DNA binding of p65-NF-kappaB.	GSK1210151A	0-8	interleukin 6	Mus musculus	57-61
27732564-6	2016	Mechanistically, I-BET151 treatment abrogated UUO-induced phosphorylation of epidermal growth factor receptor and platelet growth factor receptor-beta.	GSK1210151A	17-25	epidermal growth factor receptor	Homo sapiens	77-109
27276402-9	2016	Incubation with I-BET151 induced downregulation of MYCL1 in U266 cells.	GSK1210151A	16-24	MYCL proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
26416749-7	2015	The BRD4 inhibitor I-BET151 downregulated these SE-associated genes, yet also has anti-leukaemic activity.	GSK1210151A	19-27	bromodomain containing 4	Homo sapiens	4-8
25391636-5	2014	Mechanistically, I-BET151 inhibits expression of the master osteoclast regulator NFATC1 by suppressing expression and recruitment of its newly identified upstream regulator MYC.	GSK1210151A	17-25	nuclear factor of activated T cells 1	Homo sapiens	81-87
23929215-6	2014	We generated JAK2 inhibitor resistant HEL cells and showed that these retain sensitivity to I-BET151.	GSK1210151A	92-100	Janus kinase 2	Homo sapiens	13-17
23929215-7	2014	These data highlight I-BET151 as a potential alternative treatment against myeloproliferative neoplasms driven by constitutively active JAK2 kinase.	GSK1210151A	21-29	Janus kinase 2	Homo sapiens	136-140
21964340-5	2011	We show that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis.	GSK1210151A	65-76	lysine (K)-specific methyltransferase 2A	Mus musculus	136-139